The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled HIV Capacity Building Assistance (CBA) Program: Data Management, Monitoring, and Evalu

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.

Original title: “Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts”

hiv 1 reservoir inducibility and immune phenotypes after prolonged analytical treatment interruption a long term follow up study

Original title: “HIV-1 reservoir inducibility and immune phenotypes after prolonged analytical treatment interruption: a long-term follow-up study.”

retraction notice to molecular mechanism of regulating tat protein expression of pingganjiedu tcm in the treatment of aids based on network pharmacology int j biol macromol 278 2024 134599

Original title: “Retraction notice to "Molecular mechanism of regulating tat protein expression of pingganjiedu TCM in the treatment of AIDS based on network pharmacology" [Int. J. Biol. Macromol. 278 (2024) 134599].”

The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.

Original title: “GSK prepares for patent cliff with $2.5B cost-cutting plan”

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

Original title: “Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study”

Company to showcase INSTI-powered innovation across treatment and PrEP

Original title: “ViiV Healthcare to unveil new HIV treatment data at AIDS 2026”

reversible hiv associated nephropathy and concomitant encephalomyelopathy as the initial presentation of advanced untreated hiv

Original title: “Reversible HIV-Associated Nephropathy and Concomitant Encephalomyelopathy as the Initial Presentation of Advanced, Untreated HIV.”

purple urine bag syndrome in a 26 year old woman living with hiv and metastatic spinal cord compression a case report

Original title: “Purple Urine Bag Syndrome in a 26-Year-Old Woman Living with HIV and Metastatic Spinal Cord Compression: A Case Report.”

evaluation of anal cancer screening among 18 to 34 year old men who have sex with men living with hiv over a 10 year period

Original title: “Evaluation of Anal Cancer Screening Among 18-to-34-Year-Old Men Who Have Sex With Men Living With HIV Over a 10-Year Period.”

The Office of the Assistant Secretary for Health (OASH) is seeking nominations for membership on the Presidential Advisory Council on HIV/AIDS (referred to as PACHA and/or the Council). The PACHA is a federal advisory committee within the U. S. Department of Health and Human Services (HHS). Management support for the activities of this Council is the responsibility of the Office of the Assistant Secretary for Health (OASH). The qualified individuals will be nominated by the Secretary of the U.S.

Original title: “Solicitation of Nominations for Membership on the Presidential Advisory Council on HIV/AIDS”

focusing on vulnerable populations in hiv

Original title: “Focusing on vulnerable populations in HIV.”

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

Original title: “Merck, Gilead report mixed outcomes in key lung cancer, HIV studies”

While Merck and Gilead Sciences reported back-to-back late-stage victories for their weekly HIV pill, the partners also discontinued a Phase 3 program for their cancer combo after disappointing lung cancer survival data.

Original title: “Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble”

neurosymptomatic hiv csf viral escape with parkinsonism and amyotrophic lateral sclerosis like syndrome a case report

Original title: “Neurosymptomatic HIV CSF viral escape with parkinsonism and amyotrophic lateral sclerosis-like syndrome: a case report.”

pulmonary aspergillosis complicated by recurrent pneumothorax in a person living with hiv a case report

Original title: “Pulmonary aspergillosis complicated by recurrent pneumothorax in a person living with HIV: A case report.”

hiv care continuity for women in postconflict tigray assessing mother to child transmission rates infant health and cervical cancer screening

Original title: “HIV care continuity for women in postconflict Tigray: assessing mother-to-child transmission rates, infant health and cervical cancer screening.”

opsoclonus myoclonus syndrome in an hiv patient following plasmodium falciparum infection

Original title: “Opsoclonus myoclonus syndrome in an HIV patient, following plasmodium falciparum infection.”

Information about using PrEP for HIV prevention.

Original title: “Preventing HIV with PrEP”

cost effectiveness of efavirenz 600 mg vs 400 mg in people living with hiv in china

Original title: “Cost-effectiveness of efavirenz 600 mg vs. 400 mg in people living with HIV in China.”